COMPANY

Bionic Sight

Keywords: ophthalmology gene therapy retinitis pigmentosa geographic atrophy choroideremia Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD) BS01

Profile checked Oct 10, 2026

2Trials (company is sponsor)

Timeline

Jan 8, 2026 Trial start 1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD source ↗
Feb 6, 2020 Trial start Phase 1/Phase 2: BS01 in Patients With Retinitis Pigmentosa source ↗

Upcoming milestones

Dec 30, 2026 (ESTIMATED) · Phase 1/Phase 2 · BS01 in Patients With Retinitis Pigmentosa · NCT04278131
2027-12 (ESTIMATED) · 1 · A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD · NCT07158775

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT04278131	BS01 in Patients With Retinitis Pigmentosa	Phase 1/Phase 2	Recruiting	Feb 6, 2020	Dec 30, 2026 (estimated)
NCT07158775	A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD	1	Recruiting	Jan 8, 2026	2027-12 (estimated)